Spots Global Cancer Trial Database for Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer

Official Title: Phase II Study as First Line Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Study ID: NCT00315185

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Cetuximab

Study Description

Brief Summary: The purpose of this study is to determine the role of cetuximab (Erbitux) with chemotherapy for advanced colorectal carcinoma. This study will determine if this new agent can improve one's response to standard treatment.

Detailed Description: This research study is being done to determine if cetuximab will improve efficacy of standard chemotherapy. This agent targets epidermal growth factor receptor (EGFR). EGFR sits on the outside of tumor cells and controls tumor cell growth. This agent has been looked at alone and with other chemotherapy drugs in non-small-cell lung cancer (NSCLC). It has shown to be safe and can shrink tumors. There is little information about the combination of this agent with both paclitaxel and carboplatin. This study combines cetuximab with monthly carboplatin and weekly paclitaxel.